These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33038914)

  • 41. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extrahepatic Complications of Nonalcoholic Fatty Liver Disease.
    Chacko KR; Reinus J
    Clin Liver Dis; 2016 May; 20(2):387-401. PubMed ID: 27063276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity.
    Peng L; Wu S; Zhou N; Zhu S; Liu Q; Li X
    BMC Pediatr; 2021 Mar; 21(1):122. PubMed ID: 33711964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-Alcoholic Fatty Liver Disease and Vascular Disease.
    Forlano R; Mullish BH; Nathwani R; Dhar A; Thursz MR; Manousou P
    Curr Vasc Pharmacol; 2021; 19(3):269-279. PubMed ID: 32188385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
    Vanni E; Marengo A; Mezzabotta L; Bugianesi E
    Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
    Fargion S; Porzio M; Fracanzani AL
    World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The metabolic syndrome and chronic liver disease.
    Rosselli M; Lotersztajn S; Vizzutti F; Arena U; Pinzani M; Marra F
    Curr Pharm Des; 2014; 20(31):5010-24. PubMed ID: 24320032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NAFLD: a multisystem disease.
    Byrne CD; Targher G
    J Hepatol; 2015 Apr; 62(1 Suppl):S47-64. PubMed ID: 25920090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.
    Hu KC; Wang HY; Liu SC; Liu CC; Hung CL; Bair MJ; Liu CJ; Wu MS; Shih SC
    World J Gastroenterol; 2014 Jun; 20(24):7718-29. PubMed ID: 24976709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α.
    Ajmal MR; Yaccha M; Malik MA; Rabbani MU; Ahmad I; Isalm N; Abdali N
    Indian Heart J; 2014; 66(6):574-9. PubMed ID: 25634387
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications.
    Miele L; Targher G
    Expert Rev Gastroenterol Hepatol; 2015; 9(10):1243-5. PubMed ID: 26224399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
    Chinnadurai R; Chrysochou C; Kalra PA
    Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.
    Targher G; Tilg H; Byrne CD
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):578-588. PubMed ID: 33961787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.
    Pardhe BD; Shakya S; Bhetwal A; Mathias J; Khanal PR; Pandit R; Shakya J; Joshi HO; Marahatta SB
    BMC Gastroenterol; 2018 Jul; 18(1):109. PubMed ID: 29980170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.